Zealand Pharma A/S
Inside informationZealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billionCompany announcement – No. 34 / 2024 Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billion - A directed share offering to certain institutional and professional investors through an accelerated bookbuilding process previously announced has due to strong investor demand been upsized from USD 900 million / DKK 6.257 billion to approximately USD 1 billion / DKK 7 billion
Copenhagen, Denmark, 25 June 2024 – Zealand Pharma A/S (“Zealand“) (Nasdaq: ZEAL), (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines for obesity, other metabolic, and certain rare diseases, is pleased to announce that, due to strong investor demand in connection with its previously announced placing (see Company Announcement 33 / 2024), the Company has elected to increase the size of the placing from approximately USD 900 million / DKK 6.257 billion to approximately USD 1 billion / DKK 7 billion through the issuance of new shares (the “New Shares“) (the “Offering“). The Offering will be completed through an accelerated bookbuilding process in a private placement directed at institutional and professional investors in Denmark and certain other jurisdictions. Expected timetable for the Offering Bookbuilding has commenced and can close at any time. Completion of the Offering, including the admission to trading and official listing of the New Shares, is subject to the Offering not being withdrawn prior to the settlement hereof and Zealand making an announcement to that effect. Expected 25 June 2024 | Pricing and announcement of subscription price | Excepted 26 June 2024 | Subscribers are notified of their allocation | Expected 28 June 2024 | Registration of the New Shares with the Danish Business Authority | Expected 28 June 2024 | Settlement and payment against delivery of the New Shares. The New Shares will be delivered in the temporary ISIN code | Expected 1 July 2024 | Admittance to trading and official listing of the New Shares, in the ISIN code for the existing shares, DK0060257814, on Nasdaq Copenhagen A/S | Expected 2 July 2024 | Merger of the temporary ISIN code with the permanent ISIN code |
|